Search

Your search keyword '"P, Svec"' showing total 4 results
Start Over Author "P, Svec" Publication Year Range This year
4 results on '"P, Svec"'

1. Disentangling the components of a multiconfigurational excited state in isolated chromophore

Author

Ferreira, Rodrigo Cezar de Campos, Sagwal, Amandeep, Doležal, Jiří, Neuman, Tomáš, and Švec, Martin

Subjects
Physics - Atomic and Molecular Clusters
Abstract

Studying the excited states of doublets is challenging for their typically multiconfigurational character. We employ light-scanning-tunneling microscopy (light-STM) to investigate photon-induced currents on a single open-shell PTCDA anion molecule placed into a plasmonic nanocavity between a tip and a substrate, irradiated by laser. Submolecular mapping reveals a zero-bias bidirectional photocurrent strongly varying with the lateral position of the tip apex above the molecule. We elucidate the mechanism in terms of a theoretical model in which a multiconfigurational doublet state is excited and decays back to the anion ground state through sequential electron transfers with the tip and the substrate. The correspondence of the experimental and theoretical contrast proves the correlated character of the excited state which can be described as a superposition of two dominating electronic configurations. By applying bipolar voltage on the junction with the molecule, we switch the dominant recombination pathway from one of the configurations to the other, effectively disentangling the multiconfigurational state individual components through visualization of their Dyson orbitals, as corroborated by theoretical modelling., Comment: Manuscript + Supplementary information

Published
2025

2. The adaptor protein Miro1 modulates horizontal transfer of mitochondria in mouse melanoma models

Author

Novak, Jaromir, Nahacka, Zuzana, Oliveira, Gabriela L., Brisudova, Petra, Dubisova, Maria, Dvorakova, Sarka, Miklovicova, Sona, Dalecka, Marketa, Puttrich, Verena, Grycova, Lenka, Magalhaes-Novais, Silvia, Correia, Catarina Mendes, Levoux, Jennifer, Stepanek, Ludek, Prochazka, Jan, Svec, David, Reguera, David Pajuelo, Lopez-Domenech, Guillermo, Zobalova, Renata, Sedlacek, Radek, Terp, Mikkel G., Gammage, Payam A., Lansky, Zdenek, Kittler, Josef, Oliveira, Paulo J., Ditzel, Henrik J., Berridge, Michael V., Rodriguez, Anne-Marie, Boukalova, Stepana, Rohlena, Jakub, and Neuzil, Jiri

Abstract

Recent research has shown that mtDNA-deficient cancer cells (ρ0cells) acquire mitochondria from tumor stromal cells to restore respiration, facilitating tumor formation. We investigated the role of Miro1, an adaptor protein involved in movement of mitochondria along microtubules, in this phenomenon. Inducible Miro1 knockout (Miro1KO) mice markedly delayed tumor formation after grafting ρ0cancer cells. Miro1KOmice with fluorescently labeled mitochondria revealed that this delay was due to hindered mitochondrial transfer from the tumor stromal cells to grafted B16 ρ0cells, which impeded recovery of mitochondrial respiration and tumor growth. Miro1KOled to the perinuclear accumulation of mitochondria and impaired mobility of the mitochondrial network. In vitroexperiments revealed decreased association of mitochondria with microtubules, compromising mitochondrial transfer via tunneling nanotubes (TNTs) in mesenchymal stromal cells. Here we show the role of Miro1 in horizontal mitochondrial transfer in mouse melanoma models in vivoand its involvement with TNTs.

Published
2025
Full Text
View/download PDF

3. Comparable outcomes after busulfan- or treosulfan-based conditioning for allo-HSCT in children with ALL: results of FORUM

Author

Kalwak, Krzysztof, Moser, Laura M., Pötschger, Ulrike, Bader, Peter, Kleinschmidt, Katharina, Meisel, Roland, Dalle, Jean-Hugues, Yesilipek, Akif, Balduzzi, Adriana, Krivan, Gergely, Goussetis, Evgenios, Staciuk, Raquel, Sedlacek, Petr, Pichler, Herbert, Svec, Peter, Gabriel, Melissa, Güngör, Tayfun, Bilic, Ernest, Buechner, Jochen, Renard, Marleen, Vettenranta, Kim, Ifversen, Marianne, Diaz-de-Heredia, Cristina, Stein, Jerry, Toporski, Jacek, Bierings, Marc, Peters, Christina, Ansari, Marc, and Locatelli, Franco

Abstract

•Chemotherapy conditioning with BU- or TREO-based regimens yields comparable outcomes for allo-HSCT in children with ALL.•Either regimen can be effectively and safely used in patients >4 years when TBI is contraindicated or unavailable.

Published
2025
Full Text
View/download PDF

4. Auer rod-positive acute leukemia with predominantly lymphoid immunophenotype: Report on 11 cases and review of literature.

Author

Hrusak O, Stancikova J, Vodickova E, Podolska T, Möricke A, Attarbaschi A, Dworzak M, Sestakova Z, Svec P, Zaliova MK, Janotova I, Zapletal O, Mejstrikova E, and Stary J

Subjects
Adolescent, Child, Child, Preschool, Female, Humans, Infant, Male, Follow-Up Studies, Leukemia, Myeloid, Acute pathology, Leukemia, Myeloid, Acute therapy, Leukemia, Myeloid, Acute immunology, Precursor Cell Lymphoblastic Leukemia-Lymphoma pathology, Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma immunology, Immunophenotyping
Abstract

Background: Auer rods (AuRs) are prominent intracellular structures found almost exclusively in myeloid cell malignancies, such as acute myeloid leukemia (AML), chronic and juvenile myelomonocytic leukemia and myelodysplastic syndrome. Extremely rare AuRs have been reported in patients with acute lymphoblastic leukemia (ALL) or among ambiguous lineage leukemia patients with a dominantly lymphoblastic immunophenotype., Procedure: We report diagnostic and follow-up data of an international cohort of 11 children suffering from leukemias with AuRs and with significant presence of T and myeloid markers, majority of whom categorized as early T-cell precursor (ETP, n = 7); or T-ALL (ETP status unknown, n = 2), ALAL (acute leukemia of ambiguous lineage, n = 1), and AML reclassified from ALAL (n = 1). We described other diagnostic details and treatment types and responses. Moreover, we summarize previously published data., Results: Among the four patients who started and remained on ALL-type therapy, all were in the first complete remission, whereas both patients who started and remained on AML-type therapy relapsed and died. Of the patients who followed either a combined ALL/AML protocol (Interfant 06) or who switched from one of the two types of therapy to the other, one patient died, and the remaining four were in first complete remission at the most recent follow-up. We also searched for similar cases in the literature and found only three additional children with nonmyeloid leukemia and AuRs and 10 adults with this type of leukemia., Conclusions: Briefly, ALL- or combined ALL/AML-type therapy may be effective for treating AuR-positive leukemia patients with a lymphoid immunophenotype., (© 2024 The Author(s). Pediatric Blood & Cancer published by Wiley Periodicals LLC.)

Published
2025
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results